Nov 6th, 2024
Novo Nordisk CFO on Wegovy Sales, Cagrisema Timings
Novo Nordisk Chief Financial Officer Karsten Munk Knudsen talks with Bloomberg Television after the Copenhagen-based drugmaker said sales of the blockbuster weight-loss drug Wegovy leapt by about 50% in the US last quarter. Knudsen also discusses Novo’s next-generation obesity treatment, CagriSema, which is undergoing a large study that’s due to deliver results by December.
